Patents Examined by Phillip Gambel
  • Patent number: 10669342
    Abstract: The present invention relates to anti-human OX4OL antibodies, new medical uses and methods.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: June 2, 2020
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosma{hacek over (c)}
  • Patent number: 10669343
    Abstract: The present invention relates to antagonistic antibodies specifically binding CD154, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: June 2, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Johan Fransson, Galina Obmolova, Anish Suri, Fang Teng, Alexey Teplyakov, Hong Zhou, Jocelyn Leu
  • Patent number: 10654935
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: November 1, 2016
    Date of Patent: May 19, 2020
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosma{hacek over (c)}
  • Patent number: 10640567
    Abstract: The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10?10 M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: May 5, 2020
    Assignee: ALLIGATOR BIOSCIENCE AB
    Inventors: Peter Bo Joakim Ellmark, Eva Maria Dahlen
  • Patent number: 10633434
    Abstract: The present invention provides monoclonal antibodies that bind to the complement factor 5 (C5) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to C5 protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing C5 activity, thus providing a means of treating or preventing a C5-related disease or disorder in humans. In some embodiments, the invention provides for an anti-C5 antibody that has improved pharmacokinetic and pharmacodynamic properties, e.g., a half-life of more than 10 days.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: April 28, 2020
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Ying Hu, Adrianna Latuszek, Carmelo Romano, William Olson
  • Patent number: 10632170
    Abstract: Methods for treating, preventing or delaying onset of tumor formation and other forms of cancer are disclosed. The methods involve administration of a complement inhibitor to inhibit C5a receptor signaling in the tumor microenvironment.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: April 28, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: John D. Lambris, Maciej M. Markiewski
  • Patent number: 10633444
    Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: April 28, 2020
    Assignee: Celldex Therapeutics, Inc.
    Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He, Tom O'Neill, Andrea Crocker, Karuna Sundarapandiyan, Lawrence J. Thomas, Jenifer Widger
  • Patent number: 10626181
    Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: April 21, 2020
    Assignees: AGENUS INC., MEMORIAL SLOAN-KETTERING CANCER CENTER, LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
    Inventors: Marc Van Dijk, Ekaterina V. Breous-Nystrom, Volker Seibert, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Hao Tang, Taha Merghoub, David A. Savitsky, Jeremy Waight, Nicholas S. Wilson
  • Patent number: 10604563
    Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement Factor Bb. Specifically, the disclosure is related to anti-complement Factor Bb antibodies.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: March 31, 2020
    Assignee: Allergan, Inc.
    Inventors: Yanbin Liang, Chen Li, Iris Lee, Victor M. Guzman
  • Patent number: 10597460
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: March 24, 2020
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
  • Patent number: 10588976
    Abstract: Anti-CD40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: March 17, 2020
    Assignee: Novartis AG
    Inventors: Claudia Mueller, Matthias Willmann
  • Patent number: 10584164
    Abstract: The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
    Type: Grant
    Filed: January 14, 2019
    Date of Patent: March 10, 2020
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Bruce A. Andrien, Jr., Douglas L. Sheridan, Paul P. Tamburini, Yi Wang
  • Patent number: 10577425
    Abstract: The invention provides an antibody or fragment thereof that specifically binds to human CD40.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: March 3, 2020
    Assignee: ALLIGATOR BIOSCIENCE AB
    Inventors: Peter Ellmark, Karin Enell Smith, Niina Veitonmaki
  • Patent number: 10561728
    Abstract: The present invention relates to antibodies specific for a particular epitope on CD40 and antibodies that bind CD40 and have particular functional characteristics. The present invention also relates to fragments of these antibodies, uses of the antibodies for reduction or treatment of transplant rejection and graft-versus-host disease, and methods for making the antibodies.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: February 18, 2020
    Assignees: Beth Israel Deaconess Medical Center, Inc., Emory University
    Inventors: Keith A. Reimann, Rijian Wang, Christian P. Larsen
  • Patent number: 10544228
    Abstract: Antibody polypeptides that specifically bind a novel epitope of human CD40 are provided. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides are useful in the treatment of diseases involving CD40 activation, such as autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VL or VH domain. The half-life of the antibody polypeptides may be increased by modifying the antibody polypeptides to be dual specific reagents that can also bind human serum albumin (HSA).
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: January 28, 2020
    Assignees: Bristol-Myers Squibb Company, Domantis Limited
    Inventors: Anish Suri, Steven Sheriff, Suzanne Suchard, Aaron Yamniuk, Stanley Krystek, James Tamura, James Bryson, Steven Grant, Philip Drew
  • Patent number: 10544209
    Abstract: Provided herein are methods of replicating a large scale eculizumab production cell culture in a small scale culture.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: January 28, 2020
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Hunter F. Malanson, Pratik Jaluria
  • Patent number: 10544229
    Abstract: The present invention relates to agonistic antibodies specifically binding human CD40, polynucleotides encoding the antibodies or antigen-binding fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: January 28, 2020
    Assignee: Janssen Biotech, Inc.
    Inventors: Johan Fransson, Paul Kim, Michael Quigley, Andressa Smith, Alexey Teplyakov, Hong Zhou
  • Patent number: 10533054
    Abstract: Provided is a fusion protein comprising an agonist for CD40 and an agonist for OX40. Compositions comprising the fusion protein and methods of use are also provided.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: January 14, 2020
    Assignee: Thomas Jefferson University
    Inventors: Mark L. Tykocinski, Matthew Charles Weber
  • Patent number: 10519243
    Abstract: The present disclosure provides novel anti-CD40 antibodies, compositions including the new antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: December 31, 2019
    Assignee: AbbVie Biotherapeutics Inc.
    Inventors: Diane Sau Mun Cohen, Diane Hollenbaugh, Shiming Ye
  • Patent number: 10479828
    Abstract: The present application relates to methods and compositions employing an antibody that inhibits activation of the complement system and can be used to prevent or treat a pulmonary disease or condition.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: November 19, 2019
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventor: Yi Wang